$2.23
-0.11-4.70%
Last update: 11:22 AM
15 minutes delayed
Comments
Loading...
ProKidney
PROKNASDAQ
ProKidney (NASDAQ:PROK) Stock, Analyst Ratings, Price Targets, Forecasts
ProKidney Corp has a consensus price target of $10.86 based on the ratings of 8 analysts. The high is $18 issued by UBS on October 18, 2022. The low is $3 issued by Morgan Stanley on March 7, 2024. The 3 most-recent analyst ratings were released by Jefferies, B of A Securities, and Morgan Stanley on June 10, 2024, May 29, 2024, and March 7, 2024, respectively. With an average price target of $4.33 between Jefferies, B of A Securities, and Morgan Stanley, there's an implied 94.32% upside for ProKidney Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
B of A Securities
Morgan Stanley
BTIG
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for ProKidney
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/10/2024 | Buy Now | 169.06% | Jefferies | Kelly Shi | $15 → $6 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | 79.37% | B of A Securities | Jason Gerberry | $3 → $4 | Maintains | Neutral | Get Alert |
| 03/07/2024 | Buy Now | 34.53% | Morgan Stanley | Judah Frommer | → $3 | Assumes | → Equal-Weight | Get Alert |
| 01/02/2024 | Buy Now | -10.31% | B of A Securities | Jason Gerberry | $8 → $2 | Downgrade | Buy → Neutral | Get Alert |
| 07/25/2023 | Buy Now | 617.49% | BTIG | Justin Zelin | → $16 | Initiates | → Buy | Get Alert |
| 12/21/2022 | Buy Now | 572.65% | Jefferies | Kelly Shi | → $15 | Initiates | → Buy | Get Alert |
| 11/10/2022 | Buy Now | 482.96% | Morgan Stanley | Vikram Purohit | → $13 | Initiates | → Equal-Weight | Get Alert |
| 10/18/2022 | Buy Now | 707.17% | UBS | Colin Bristow | → $18 | Initiates | → Buy | Get Alert |
| 10/14/2022 | Buy Now | 617.49% | Citigroup | Yigal Nochomovitz | → $16 | Initiates | → Buy | Get Alert |
| 09/02/2022 | Buy Now | — | Evercore ISI Group | Jonathan Miller | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for ProKidney (PROK) stock?
The latest price target for ProKidney (NASDAQ:PROK) was reported by Jefferies on June 10, 2024. The analyst firm set a price target for $6.00 expecting PROK to rise to within 12 months (a possible 169.06% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProKidney (PROK)?
The latest analyst rating for ProKidney (NASDAQ:PROK) was provided by Jefferies, and ProKidney maintained their buy rating.
When was the last upgrade for ProKidney (PROK)?
There is no last upgrade for ProKidney
When was the last downgrade for ProKidney (PROK)?
The last downgrade for ProKidney Corp happened on January 2, 2024 when B of A Securities changed their price target from $8 to $2 for ProKidney Corp.
When is the next analyst rating going to be posted or updated for ProKidney (PROK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProKidney, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProKidney was filed on June 10, 2024 so you should expect the next rating to be made available sometime around June 10, 2025.
Is the Analyst Rating ProKidney (PROK) correct?
While ratings are subjective and will change, the latest ProKidney (PROK) rating was a maintained with a price target of $15.00 to $6.00. The current price ProKidney (PROK) is trading at is $2.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.